March 26, 2019
InSysBio announces their participation at 15th Essential Protein Engineering Summit being held on April 8-12 in Boston, MA. The company welcomes visitors at the booth #200. Also InSysBio is presenting a poster “Selection of First-in-Human Study Dose for Antibodies and Antibody Constructs Using Quantitative Systems Pharmacology Modeling” by Oleg Demin Jr.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit insysbio.com.
| ← | November 2016 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
1.
28 Nov 2016 12:26
A New Mathematical Model of the Eosinophil Lifecycle Shows Irrelevance of the Asthma Biomarker Choice
Moscow, Russia - November 29th, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), one of the pioneers in bio-modeling and simulation announced the study made in collaboration with scientists of two pharmaceutical leaders: MedImmune and AstraZeneca.
|
29
|
30
| ||||
Thank you for your message! We will get back to you shortly.
